Novel Drug Tied to Slowed Disease Progression in Relapsing MS
The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.
Medscape Medical News
source https://www.medscape.com/viewarticle/975368?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975368?src=rss
Comments
Post a Comment